Literature DB >> 1633889

Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.

D Navot1, P A Bergh, N Laufer.   

Abstract

OBJECTIVE: To overview the world literature on ovarian hyperstimulation syndrome (OHSS) and modes of prevention and treatment of OHSS. STUDY SELECTION: All the pertinent literature on OHSS, its prevention, and strategies for treatment were reviewed. PREVENTION: Key to prevention is proper identification of the population at risk, which includes women with either the hormonal or the morphological signs of polycystic ovarian disease, high serum estradiol (E2) before human chorionic gonadotropin (hCG) administration (E2 greater than 4,000 pg/mL), multiple follicular response (greater than 35), younger age, and lean habitus. When a high risk situation is recognized, ovulatory dose of hCG may be reduced, avoided (with cycle cancellation), or substituted by gonadotropin-releasing hormone or its agonist. Luteal support with hCG is to be bypassed. To minimize risk of OHSS, endogenous pregnancy-drived hCG may be eluded by judicious cryopreservation of all embryos. Last, follicular aspiration will allow higher levels of E2 and larger number of follicles to be matured with lesser risk of OHSS than conventional ovulation induction without follicular aspiration. TREATMENT: In-house for the severe and intensive care for the critical form. Meticulous fluid and electrolyte balance using both crystalloids and colloids (albumin) until hemoconcentration abates. Paracentesis is indicated for tight ascites, deteriorating kidney functions, and symptomatic relief. Diuretics may be prudently used once hemodilution is achieved. Dopamine drip may be used as a renal rescue, whereas heparin is indicated for thromboembolic phenomena and surgery reserved for abdominal catastrophies. Therapeutic interruption of an early gestation may be lifesaving when all other measures have failed.
CONCLUSIONS: Although severe and critical OHSS may not be completely avoided, early recognition of high-risk factors, judicious prevention schemes, and treatment strategies should reduce the complication and long-term sequelae of this iatrogenic syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633889     DOI: 10.1016/s0015-0282(16)55188-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  101 in total

1.  An IVF fallacy: multiple pregnancy risk is lower for older women.

Authors:  S Senöz; A Ben-Chetrit; R F Casper
Journal:  J Assist Reprod Genet       Date:  1997-04       Impact factor: 3.412

Review 2.  Ovarian hyperstimulation syndrome: a review of pathophysiology.

Authors:  P A Bergh; D Navot
Journal:  J Assist Reprod Genet       Date:  1992-10       Impact factor: 3.412

3.  No association between the microsatellite polymorphism (TTTTA)n in the promoter of the CYP11A gene and ovarian hyperstimulation syndrome.

Authors:  Polonca Ferk; Ksenija Gersak; Natasa Teran
Journal:  J Assist Reprod Genet       Date:  2006-01-04       Impact factor: 3.412

Review 4.  Understanding ovarian hyperstimulation syndrome.

Authors:  Anne Delbaere; Guillaume Smits; Anne De Leener; Sabine Costagliola; Gilbert Vassart
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

5.  What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study.

Authors:  Theoni B Tarlatzi; Christos A Venetis; Fabienne Devreker; Yvon Englert; Anne Delbaere
Journal:  J Assist Reprod Genet       Date:  2017-07-14       Impact factor: 3.412

Review 6.  [Jugular vein thrombosis caused by hypercoagulability following in-vitro fertilization-activated protein C resistance and immobilization].

Authors:  K Stölzel; S Jovanovic; A E Albers
Journal:  HNO       Date:  2013-03       Impact factor: 1.284

7.  Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.

Authors:  Jhansi Reddy; Volkan Turan; Giuliano Bedoschi; Fred Moy; Kutluk Oktay
Journal:  J Assist Reprod Genet       Date:  2014-05-23       Impact factor: 3.412

8.  Could pretreatment with oral contraceptives before pituitary down regulation reduce the incidence of ovarian hyperstimulation syndrome in the IVF/ICSI procedure?

Authors:  Lan Wang; Yiqing Zhao; Xiyuan Dong; Kai Huang; Rui Wang; Licheng Ji; Ya Wang; Hanwang Zhang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

9.  Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome.

Authors:  L Rinaldi; F Lisi; H Selman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

Review 10.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.